Fig. 3From: Long-term effectiveness and tolerability of galcanezumab in patients with migraine excluded from clinical trials: real world evidence of 1055 patients with 1 year follow-up from the Galca-Only registryResponder rate within the different groups according to the ITT analysisBack to article page